Re-searching anthracycline therapy

Breast Cancer Research and Treatment

Volumn 123, Issue 1, 2010, Pages 171-175

  Oakman, Catherine ^a   Moretti, Erica ^a   Leo, Angelo Di ^a  

^a HOSPITAL OF PRATO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR MARKER;

BREAST CANCER; CHROMOSOME 17; COPY NUMBER VARIATION; DNA REPAIR; DNA STRAND BREAKAGE; DRUG DNA BINDING; DRUG EFFICACY; DRUG TARGETING; GENE AMPLIFICATION; GENETIC POLYMORPHISM; HUMAN; MULTIPLE CYCLE TREATMENT; NOTE; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; FEMALE; GENETICS; META ANALYSIS (TOPIC);

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 77955772551     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0985-x     Document Type: Note

References (37)

1. KI Pritchard LE Shepherd FP O'Malley,, et al. 2006 HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 354 2103 2111 10.1056/NEJMoa054504 1:CAS:528:DC%2BD28XkslCku7s%3D 16707747 (Pubitemid 43736610)
2. JMS Bartlett AF Munro DA Cameron,, et al. 2008 Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trials J Clin Oncol 26 5027 5035 10.1200/JCO.2007.14.6597 1:CAS:528:DC%2BD1cXhsVGhsrrE 18768436
3. M De Laurentiis F Caputo E Massarelli,, et al. 2001 HER2 expression and anthracycline effect: results from the Naples GUN3 randomised trial (abstr 133) Proc Am Soc Clin Oncol 20 A133
4. A Di Leo D Gancberg D Larsimont,, et al. 2002 HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil Clin Cancer Res 8 1107 1116 12006526
5. AS Knoop H Knudsen E Balslev,, et al. 2005 Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil J Clin Oncol 23 7483 7490 10.1200/JCO.2005.11.007 1:CAS:528:DC%2BD2MXht1WrsrzK 16234514 (Pubitemid 46291811)
6. A Moliterni S Menard P Valagussa,, et al. 2003 HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer J Clin Oncol 21 458 462 10.1200/JCO.2003.04.021 1:CAS:528:DC%2BD2cXpsVGrtLo%3D 12560435 (Pubitemid 46606475)
7. S Paik J Bryant E Tan-Chiu,, et al. 2000 HER2 and choice of adjuvant chemotherapy for invasive breast cancer: national surgical adjuvant breast and bowel project protocol B-15 J Natl Cancer Inst 92 1991 1998 10.1093/jnci/92.24. 1991 1:CAS:528:DC%2BD3MXkvF2rsw%3D%3D 11121461
8. A Gennari MP Sormani P Pronzato,, et al. 2008 HER-2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 14 20 10.1093/jnci/djm252 1:CAS:528:DC%2BD1cXit1Cku7o%3D 18159072 (Pubitemid 351767337)
9. C Desmedt E Azambuja D Larsimont,, et al. 2009 Predicting the efficacy of anthracyclines in breast cancer (BC) patients: results of the neoadjuvant TOP trial (abstract 523) J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695
10. F O'Malley S Chia D Tu,, et al. 2009 Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy J Natl Cancer Inst 101 644 650 10.1093/jnci/djp067 19401546
11. D Slamon W Eiermann N Robert,, et al. 2006 BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients (abstract 52) Breast Cancer Res Treat 100 s1
12. M Tanner J Isola T Wiklund,, et al. 2006 Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: scandinavian breast cancer group trial 9401 J Clin Oncol 24 2428 2436 10.1200/JCO.2005.02.9264 1:CAS:528:DC%2BD28XmtVOmsLc%3D 16682728 (Pubitemid 46630618)
13. TA Järvinen M Tanner V Rantanen,, et al. 2000 Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to the topoisomerase II inhibitor doxorubicin in breast cancer Am J Pathol 156 839 847 10702400
14. JM Bartlett AF Munro JA Dunn,, et al. 2010 Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK national epirubicin adjuvant trial (NEAT/BR9601) Lancet Oncol 11 266 274 10.1016/S1470-2045(10)70006-1 1:CAS:528:DC%2BC3cXisFGrtr8%3D 20079691
15. LN Harris G Broadwater M Abu-Khalaf,, et al. 2009 Topoisomerase IIα amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013 J Clin Oncol 21 3430 3436 10.1200/JCO.2008.18.4085
16. R Tubbs WE Barlow GT Budd,, et al. 2009 Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status J Clin Oncol 27 3881 3886 10.1200/JCO.2008.20.1566 1:CAS:528:DC%2BD1MXhtFCgsb3P 19620488
17. A Di Leo J Isola F Piette,, et al. 2008 A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy (abstract 705) Breast Cancer Res Treat 107 24s
18. JM Bartlett A Munro C Desmedt,, et al. 2009 Duplication of chromosome 17 CEP predicts for anthracycline benefit: a meta-analysis of 4 trials (abstract 4030) Cancer Res 69 24s
19. Gunnarsdottir KA, Jensen M, Zahrieh D, et al (2010) CEF is superior to CMF for tumours with TOP2A aberrations: a subpopulation treatment effect pattern plot (STEPP) analysis on danish breast cancer cooperative study group 89D. Breast Cancer Res Treat
20. B Ejlertsen HT Mouridsen MB Jensen,, et al. 2007 Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer Eur J Cancer 43 877 884 10.1016/j.ejca.2007.01.009 1:CAS:528:DC%2BD2sXisleitL0%3D 17306974 (Pubitemid 46394520)
21. KV Nielsen B Ejlertsen S Møller,, et al. 2008 The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D Acta Oncol 47 725 734 10.1080/02841860801995396 1:CAS:528: DC%2BD1cXnsFeiur8%3D 18465341 (Pubitemid 351878451)
22. HL McArthur LK Tan S Patil,, et al. 2009 High resolution representational oligonucleotide microarray analysis (ROMA) suggests that TOPO2 and HER2 coamplification is uncommon in human breast cancer (abstract 2023) Cancer Res 69 2s 10.1158/0008-5472.CAN-08-1230
23. TA Jarvinen J Kononen M Pelto-Huikko J Isola 1996 Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 over expression in breast cancer Am J Pathol 148 2073 2082 1:STN:280:DyaK283jsVaruw%3D%3D 8669491
24. RE Mueller RK Parkes I Andrulis FP O'Malley 2004 Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples Genes Chromosom Cancer 39 288 297 10.1002/gcc.20008 1:CAS:528:DC%2BD2cXivFKjsbw%3D 14978790 (Pubitemid 38326310)
25. D Tan C Marchio R Jones,, et al. 2008 Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients Breast Cancer Res Treat 111 27 44 10.1007/s10549-007-9756-8 1:CAS:528:DC%2BD1cXos1Wnsbs%3D 17922188 (Pubitemid 352009225)
26. DJ Slamon J Mackey N Robert,, et al. 2007 Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease (abstract 13) Breast Cancer Res Treat 106 5
27. FC Bidard MC Matthieu P Chollet,, et al. 2008 p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes Ann Oncol 19 1261 1265 10.1093/annonc/mdn039 18325917 (Pubitemid 351916575)
28. C Le Tourneau S Dettwiler V Laurence,, et al. 2007 47% pathologic complete response rate to anthracyclines-based associated with high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients (abstract 4010) Breast Cancer Res Treat 106 s169
29. YY Mo WT Beck 1997 Heterogeneus expression of DNA topoisomerase II alpha isoforms in tumor cell lines Oncol Res 9 193 204 1:CAS:528:DyaK1cXhtlOnsbo%3D 9268990
30. A Oloumi SH MacPhail PJ Johnston,, et al. 2000 Changes in subcellular distribution of topoisomerase II alpha correlate with etoposide resistance in multicell spheroid and xenograft tumours Cancer Res 60 5747 5753 1:CAS:528:DC%2BD3cXnvVSntro%3D 11059769
31. A Munro D Cameron J Thomas,, et al. 2009 BUBR1, MAD2: novel markers for predicitng beneift from adjuvant anthracyclines? (abstract 2124) Cancer Res 69 24s
32. AA Rodriguez M Rimawi M-F Wu,, et al. 2009 A BRCA1-like, 25-gene assay predicts for anthracycline-chemosensitivity in sporadic triple-negative breast cancer (abstract 110) Cancer Res 69 24s 10.1158/0008-5472.CAN-08-1921
33. GL Willemoe PB Hertel A Bartels,, et al. 2009 Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n = 647) with primary breast cancer. A danish breast cancer cooperative group study Eur J Cancer 45 2528 2536 10.1016/j.ejca.2009.05.029 1:CAS:528:DC%2BD1MXhtVKls7vK 19535243
34. B Ejlertsen MB Jensen KV Nielsen,, et al. 2009 HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients J Clin Oncol 28 984 990 10.1200/JCO.2009.24. 1166 20038724
35. A Potti H Dressman A Bild,, et al. 2006 Genomic signatures to guide the use of chemotherapeutics Nat Med 12 1294 1300 10.1038/nm1491 1:CAS:528:DC%2BD28XhtFKlsLfM 17057710 (Pubitemid 44706932)
36. Desmedt C (2010) Anthracyclines and topoisomerase II alpha-what is beyond? Proceedings of the European Breast Cancer Conference, Barcelona
37. P Farmer H Bonnefoi P Anderle,, et al. 2009 A stroma-related gene signature predicts response to neoadjuvant chemotherapy in breast cancer Nat Med 15 68 74 10.1038/nm.1908 1:CAS:528:DC%2BD1MXhtVyjsQ%3D%3D 19122658